抄録
Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports suggested that, since CD8+ T cells after the administration of ICIs increase the RANKL expression to induce an immunosuppressive tumor microenvironment in melanoma, denosumab might enhance the anti-tumor effects of immune checkpoint inhibitors, such as nivolumab and ipilimumab. In this report, we present a case of multiple metastatic melanoma with nivolumab, ipilimumab plus denosumab combined therapy.
本文言語 | English |
---|---|
ページ(範囲) | 829-833 |
ページ数 | 5 |
ジャーナル | Case Reports in Oncology |
巻 | 12 |
号 | 3 |
DOI | |
出版ステータス | Published - 2019 9月 1 |
ASJC Scopus subject areas
- 腫瘍学